582 related articles for article (PubMed ID: 12747748)
21. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
[TBL] [Abstract][Full Text] [Related]
22. p53 as an immunotherapeutic target in head and neck cancer.
Hoffmann TK; Bier H; Donnenberg AD; Whiteside TL; De Leo AB
Adv Otorhinolaryngol; 2005; 62():151-60. PubMed ID: 15608425
[TBL] [Abstract][Full Text] [Related]
23. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
24. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.
Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T
Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043
[TBL] [Abstract][Full Text] [Related]
25. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
26. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
[TBL] [Abstract][Full Text] [Related]
27. DCs pulsed with novel HLA-A2-restricted CTL epitopes against hepatitis C virus induced a broadly reactive anti-HCV-specific T lymphocyte response.
Guo Z; Zhang H; Rao H; Jiang D; Cong X; Feng B; Wang J; Wei L; Chen H
PLoS One; 2012; 7(6):e38390. PubMed ID: 22701633
[TBL] [Abstract][Full Text] [Related]
28. Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients.
Kiessling A; Schmitz M; Stevanovic S; Weigle B; Hölig K; Füssel M; Füssel S; Meye A; Wirth MP; Rieber EP
Int J Cancer; 2002 Dec; 102(4):390-7. PubMed ID: 12402309
[TBL] [Abstract][Full Text] [Related]
29. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.
Disis ML; Smith JW; Murphy AE; Chen W; Cheever MA
Cancer Res; 1994 Feb; 54(4):1071-6. PubMed ID: 7508819
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.
Barfoed AM; Petersen TR; Kirkin AF; Thor Straten P; Claesson MH; Zeuthen J
Scand J Immunol; 2000 Feb; 51(2):128-33. PubMed ID: 10652158
[TBL] [Abstract][Full Text] [Related]
31. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
32. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
[TBL] [Abstract][Full Text] [Related]
33. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
[TBL] [Abstract][Full Text] [Related]
34. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
35. Isolation of broadly reactive, tumor-specific, HLA Class-I restricted CTL from blood lymphocytes of a breast cancer patient.
Verdegaal EM; Huinink DB; Hoogstraten C; Marijnissen AK; Gorsira MB; Claas FH; Osanto S
Hum Immunol; 1999 Dec; 60(12):1195-206. PubMed ID: 10626733
[TBL] [Abstract][Full Text] [Related]
36. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.
Sakakura K; Chikamatsu K; Furuya N; Appella E; Whiteside TL; Deleo AB
Clin Immunol; 2007 Oct; 125(1):43-51. PubMed ID: 17631051
[TBL] [Abstract][Full Text] [Related]
37. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ
Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087
[TBL] [Abstract][Full Text] [Related]
38. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells.
Salazar-Onfray F; Nakazawa T; Chhajlani V; Petersson M; Kärre K; Masucci G; Celis E; Sette A; Southwood S; Appella E; Kiessling R
Cancer Res; 1997 Oct; 57(19):4348-55. PubMed ID: 9331097
[TBL] [Abstract][Full Text] [Related]
39. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
[TBL] [Abstract][Full Text] [Related]
40. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]